The FDA rejected the promising skin cancer drug RP1 twice, leaving many puzzled and worried about what this means for other drug approvals ...

Replimune’s (REPL) investment thesis changed dramatically this week after the FDA rejected its lead cancer therapy, RP1, for ...

U.S. Food and Drug Administration Commissioner Marty Makary, under pressure, defends himself in an interview with CNBC's David Faber.

During Dr. Martin Makary’s tenure as commissioner, the FDA faced pushback over high-profile drug rejections for Replimune and ...

The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat ...

Shares of Replimune Group continued their downward spiral on Monday after the biotechnology company cautioned that it was facing mass layoffs and cutbacks in its manufacturing operations after ...

FDA rejects melanoma drug vusolimogene with nivolumab, citing insufficient evidence from Replimune’s phase 2 and 3 trials.

As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer. | As Bicara Therapeutics lines up ...

FDA Commissioner Marty Makary has publicly defended the agency’s decision to reject Replimune’s melanoma drug RP1, citing insufficient trial data and the absence of a control group. The move has drawn ...

Replimune Group, Inc. is rated a Buy on the ability for REPL to court surprising and bold turnarounds. Learn more about REPL ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...